IL17A and myeloid sarcoma: In MS patients, Th17 frequency, serum levels of IL-17, and IL-17 production by PBMC are higher during relapses (68, 69), and Th17 and Th17-related cytokines may be affected by immunomodulatory therapeutics employed in MS (70–72).